Roivant Sciences (ROIV) Stock Forecast & Price Target

$11.38

+0.17 (+1.52%)

(As of 10/4/2024 ET)

Roivant Sciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
1

Buy
9

Based on 10 Wall Street analysts who have issued ratings for Roivant Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a hold rating, and 9 have given a buy rating for ROIV.

Consensus Price Target

$17.39
52.80% Upside

According to the 10 analysts' twelve-month price targets for Roivant Sciences, the average price target is $17.39. The highest price target for ROIV is $23.00, while the lowest price target for ROIV is $12.50. The average price target represents a forecasted upside of 52.80% from the current price of $11.38.

Get the Latest News and Ratings for ROIV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Roivant Sciences and its competitors.

ROIV Analyst Ratings Over Time

Type	Current Forecast 10/7/23 to 10/6/24	1 Month Ago 9/7/23 to 9/6/24	3 Months Ago 7/9/23 to 7/8/24	1 Year Ago 10/7/22 to 10/7/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$17.39	$17.10	$16.90	$15.38
Forecasted Upside	52.80% Upside	39.02% Upside	57.65% Upside	42.36% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Next opportunity for crypto millions (Ad)

"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive gains. This year could be off the charts. Don't let this opportunity pass you by. In crypto, timing is everything.

Go here to discover the #1 crypto set to dominate Uptober.

ROIV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ROIV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Roivant Sciences Stock vs. The Competition

Type	Roivant Sciences	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	52.80% Upside	10,592.03% Upside	7.02% Upside
News Sentiment Rating	Positive News See Recent ROIV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/19/2024	Cantor Fitzgerald 3 of 5 stars	Reiterated Rating	Overweight
9/19/2024	HC Wainwright 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00	+50.00%
9/11/2024	Bank of America 4 of 5 stars	Boost Target	Neutral ➝ Neutral	$12.00 ➝ $12.50	+2.54%
7/10/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$20.00 ➝ $22.00	+96.78%
4/3/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$16.00 ➝ $18.00	+65.44%
4/3/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$14.00 ➝ $15.00	+37.36%
Get the Latest News and Ratings for ROIV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.
3/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00	+128.40%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$17.00	+50.18%
11/15/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$17.00 ➝ $16.00	+74.86%
11/14/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$16.00 ➝ $15.00	+61.12%
1/5/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$11.00 ➝ $14.00	+85.19%
12/19/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$8.00 ➝ $10.00	+36.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:33 AM ET.

ROIV Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Roivant Sciences is $17.39, with a high forecast of $23.00 and a low forecast of $12.50.
: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ROIV shares.
: According to analysts, Roivant Sciences's stock has a predicted upside of 52.80% based on their 12-month stock forecasts.
: Roivant Sciences has been rated by research analysts at Bank of America, Cantor Fitzgerald, HC Wainwright, and Piper Sandler in the past 90 days.
: Analysts like Roivant Sciences more than other "medical" companies. The consensus rating score for Roivant Sciences is 2.90 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ROIV compares to other companies.